AstraZeneca plc (AZN) PT Set at GBX 4,000 by Goldman Sachs Group Inc.
AstraZeneca plc (LON:AZN) has been given a GBX 4,000 ($48.75) target price by research analysts at Goldman Sachs Group Inc. in a research report issued to clients and investors on Wednesday. The brokerage presently has a a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s target price would indicate a potential downside of 20.03% from the company’s current price.
Other equities analysts also recently issued research reports about the stock. Deutsche Bank AG reissued a “buy” rating and set a GBX 5,600 ($68.25) target price on shares of AstraZeneca plc in a research note on Thursday, June 30th. Citigroup Inc. reissued a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Societe Generale reissued a “buy” rating and set a GBX 6,900 ($84.10) target price on shares of AstraZeneca plc in a research note on Friday, June 24th. Berenberg Bank lifted their target price on shares of AstraZeneca plc from GBX 4,950 ($60.33) to GBX 5,400 ($65.81) and gave the stock a “buy” rating in a research note on Tuesday, July 12th. Finally, Bryan, Garnier & Co reissued a “buy” rating on shares of AstraZeneca plc in a research note on Thursday, July 28th. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 4,966.24 ($60.53).
Shares of AstraZeneca plc (LON:AZN) traded down 1.23% during midday trading on Wednesday, reaching GBX 4940.50. 2,175,785 shares of the company’s stock traded hands. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The stock’s market cap is GBX 62.50 billion. The stock has a 50 day moving average of GBX 4,996.12 and a 200-day moving average of GBX 4,492.93.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/astrazeneca-plc-azn-pt-set-at-gbx-4000-by-goldman-sachs-group-inc-2.html
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.